Vaccine adjuvants

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 39/39 (2006.01) A61P 37/04 (2006.01)

Patent

CA 2738769

The invention provides novel adjuvants and pharmaceutical composition comprising of an adjuvant alone. The invention also provides novel vaccine compositions comprising of an antigen and a novel adjuvant. The novel adjuvant as per present invention is farnesoid-X-receptor (FXR) antagonist. The invention also relates to an adjuvant for variety of antigens. The adjuvant improves antibody production specific to incorporated antigen. The adjuvant also induces cell mediated immune response.

La présente invention concerne de nouveaux adjuvants et une composition pharmaceutique comprenant un adjuvant seul. L'invention concerne également de nouvelles compositions de vaccin comprenant un antigène et un nouvel adjuvant. Le nouvel adjuvant dans la présente invention est un antagoniste du récepteur farnésoïde X (FXR). Cette invention porte également sur un adjuvant utile pour une pluralité d'antigènes. L'adjuvant améliore la production d'anticorps spécifiques contre l'antigène introduit. L'adjuvant induit également une réponse immunitaire à médiation cellulaire.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Vaccine adjuvants does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vaccine adjuvants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine adjuvants will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-2059727

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.